Recent Updates
Recently added Catalysts

stent implantation

Phase 3

Acute Coronary Syndrome | Unknown | Cardiovascular |Cardio Diagnostics Holdings Inc.|Last Updated: May 23, 2012

Success Probability

Subscribe to view

Market & Valuation

Subscribe to view

Trial Design

RandomizedACTIVE_CONTROLLEDDMCBiomarker
Total Trials1
Total Enrollment60

FDA Designations

No designations recorded

Clinical trial landscape

stent implantation · 1 trial · 1 indication

Phase 3 1
NCT01239654Activity of Platelets After Inhibition and Cardiovascular Events Optical Coherence Tomography StudyAcute Coronary Syndrome
COMPLETED60 Analytics
PHASE3COMPLETED
Activity of Platelets After Inhibition and Cardiovascular Events Optical Coherence Tomography Study
Acute Coronary SyndromeUnlock trial analytics

Study Endpoints

Primary Endpoints

Evaluate the completeness of neointimal coverage following stent implantation (everolimus vs. zotarolimus-eluting stent) in patients with ACS.
6 month

Evaluate the completeness of neointimal coverage following stent implantation (everolimus vs. zotarolimus-eluting stent) in patients with ACS. The degree of neointimal coverage will be assessed using optical coherence tomography (OCT) calculating the rate of exposed stent struts in the study stents.

Unlock Study Endpoints

Study Design & Arms

AllocationRANDOMIZED
MaskingNONE
ModelPARALLEL
PurposeDIAGNOSTIC

Treatment Arms

ArmTypeDescription
everolimusACTIVE_COMPARATOReverolimus-eluting stent
zotarolimusACTIVE_COMPARATORzotarolimus-eluting stent

Interventions

NameTypeDescription
stent implantationDEVICEimplantation of everolimus-eluting stent vs zotarolimus-eluting stent
Unlock Study Design Details

Eligibility Criteria

Age Range18 Years to N/A
SexALL
Healthy VolunteersNo
Study Sites4

Inclusion Criteria: * Diagnosis of ACS and clinical indication to PCI * Presence of 1 or more de novo stenosis equal or greater than 70% in native coronary arteries. * Patient is \> 18 years of age (or minimum age as required by local regulations). * The patient has consented to participate by sign...

Countries:Italy
Unlock Eligibility Criteria

Frequently asked questions about stent implantation

What is stent implantation used for in Acute Coronary Syndrome?

Stent implantation is a procedure used in Acute Coronary Syndrome to open narrowed or blocked coronary arteries and restore blood flow to the heart. It involves placing a small mesh tube, called a stent, into the artery to keep it open. This treatment is being studied in a Phase 3 clinical trial.

Who makes stent implantation?

Stent implantation is being developed by Cardio Diagnostics Holdings Inc., a company traded under the ticker CDIO. The company is conducting clinical research on this procedure for the treatment of Acute Coronary Syndrome.

What phase is stent implantation in?

Stent implantation is in Phase 3 clinical development. A Phase 3 trial has been completed, which studied the procedure in patients with Acute Coronary Syndrome. The trial was active-controlled and enrolled 60 participants.

What clinical trials is stent implantation in?

Stent implantation has one completed clinical trial, NCT01239654, titled 'Activity of Platelets After Inhibition and Cardiovascular Events Optical Coherence Tomography Study'. This Phase 3 trial enrolled 60 patients with Acute Coronary Syndrome in Italy and was active-controlled.

Is stent implantation FDA approved?

Stent implantation is investigational and still in clinical development. It has not been reported as FDA approved. A Phase 3 clinical trial has been completed, but approval status has not been established.

How does stent implantation work?

Stent implantation works by physically opening a narrowed or blocked coronary artery and holding it open with a stent, a small mesh tube. This restores blood flow to the heart muscle. The procedure is being studied in patients with Acute Coronary Syndrome.